Protagonist Therapeutics has appointed David Y. Liu, Ph.D., chief scientific officer. With 26 years of biotechnology industry experience, Liu is a former vice president of research and a corporate officer at FibroGen with knowledge and expertise in the fields of inflammation and fibrosis.
Liu was chief operating officer and co-founder of Trenovus, as well as a strategic advisor to several other biotechnology companies. Before that he spent seven years at FibroGen with management responsibility for all therapeutic research and drug discovery, including interim leadership of the Clinical Development department. He also spent 10 years as director of inflammation research at Scios, now part of Johnson & Johnson.